Recaída de enfermedad entre pacientes hispanos lúpicos con enfermedad renal crónica en hemodiálisis. Presentación de casos
Palabras clave:
Lupus eritematosos sistémico, diálisis renal, recurrencia, pronósticoResumen
Introducción: Los pacientes con lupus eritematoso sistémico (LES) presentan una disminución de la actividad de la enfermedad cuando evoluciona a una enfermedad renal crónica (ERC). Se han publicado recaídas de LES en esta etapa en diferentes grupos étnicos, aunque no pacientes hispanos, tradicionalmente asociados a peor pronóstico.
Objetivo: Describir los casos de pacientes con ERC en hemodiálisis con diagnóstico de recaída de la enfermedad.
Presentación de casos: Se presentan 4 casos, 2 varones y 2 mujeres con una edad promedio de 28 años. Tuvieron un promedio de score de SLEDAI sin criterios renales de 20.25, quienes presentaron exacerbaciones de diferentes características. Todos recibieron tratamiento inmunosupresor y fallecieron 2 pacientes.
Conclusiones: Nuestro sistema de salud debería establecer estrategia de seguimiento adecuado a estos pacientes con evaluaciones frecuentes de la actividad de su enfermedad de tal forma que permita hacer un diagnóstico y tratamiento temprano. Nuestro sistema de salud debe instaurar medidas de seguimiento de los pacientes con LES en hemodiálisis para el diagnóstico y tratamiento temprano de las recaídas por LES.
Palabras claves: Lupus eritematosos sistémico, diálisis renal, recurrencia, pronóstico.
Descargas
Citas
1. Rees F, Doherty M, Grainge MJ, Lanyon P, Zhang W. The worldwide incidence and prevalence of systemic lupus erythematosus: a systematic review of epidemiological studies. Rheumatology (Oxford) [Internet]. 2017 Nov [cited 23/08/2019]; 56(11):1945-1961. Available from: https://academic.oup.com/rheumatology/article-lookup/doi/10.1093/rheumatology/kex260
2. Rees F, Doherty M, Grainge M, Davenport G, Lanyon P. The incidence and prevalence of systemic lupus erythematosus in the UK, 1999-2012. Ann Rheum Dis [Internet]. 2016 [cited 23/08/2018] Jan; 75(1):136-41. Available from: https://ard.bmj.com/content/75/1/136.long
3. Yap DY, Tang CS, Ma MK, Lam MF, Chan TM. Survival analysis and causes of mortality in patients with lupus nephritis. Nephrol Dial Transplant. [Internet]. 2012 [cited 23/08/2018]; 27(8):3248–54. Available from: https://academic.oup.com/ndt/article-lookup/doi/10.1093/ndt/gfs073
4. Maroz N, Segal MS. Lupus nephritis and end-stage kidney disease. Am J Med Sci[internet] 2013 [cited 23/08/2018]; 346(4):319–23. Available from: https://www.amjmedsci.org/article/S0002-9629 (15)30521-8/fulltext
5. Moon SJ, Park HS, Kwok SK, Ju JH, Kim HY. Predictors of end-stage renal disease and recurrence of lupus activity after initiation of dialysis in patients with lupus nephritis. Clin Exp Rheumatol [Internet]. 2013 Jan-Feb [cited 23/08/2018]; 31(1):31-9. Disponible en: http://www.clinexprheumatol.org/abstract.asp?a=5501
6. Barrera-Vargas A, Quintanar-Martínez M, Merayo-Chalico J, Alcocer-Varela J, Gómez-Martín D. Risk factors for systemic lupus erythematosus flares in patients with end-stage renal disease: a case-control study. Rheumatology (Oxford). [Internet]. 2016 Mar [cited 23/08/2018]; 55(3):429-35. Available from https://academic.oup.com/rheumatology/articlelookup/doi/10.1093/rheumatology/kev349
7. Kaul H, Girndt M, Sester U, Sester M, Kohler H. Initiation of hemodialysis treatment leads to improvement of T-cell activation in patients with end-stage renal disease. Am J Kidney Dis [Internet]. 2000 [cited 23/08/2018]; 35 (4):611–16. Available from: ttps://www.ajkd.org/article/S0272-6386(00h)70006-0/fulltext
8. Mejía-Vilet JM, Córdova-Sánchez BM, Arreola-Guerra JM, Morales-Buenrostro LE, Uribe-Uribe N. Renal flare prediction and prognosis in lupus nephritis Hispanic patients. Lupus. [Internet]. 2016 Mar [cited 23/08/2018]; 25(3):315-24. Available from: https://journals.sagepub.com/doi/abs/10.1177/0961203315606985?rfr_dat=cr_pub%3Dpubmed&url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&journalCode=lupa
9. Parikh SV, Nagaraja HN, Hebert L, Rovin BH. Renal flare as a predictor of incident and progressive CKD in patients with lupus nephritis. Clin J Am Soc Nephron [Internet] 2014 Feb [cited 23/08/2018]; 9(2):279-84. Available from: https://cjasn.asnjournals.org/content/9/2/279.long
10. Vaziri ND, Pahl MV, Crum A, Norris K. Effect of uremia on structure and function of immune system. J Ren Nutr [Internet]. 2012 [cited 23/08/2018]; 22(1):149-56. Disponible en: https://www.jrnjournal.org/article/S1051-2276(11)00210-X/fulltext
11.Althaf MM, Abdelsalam MS, Alfurayh OI. Lupus flares in two established end-stage renal disease patients with on-line hemodiafiltration during pregnancy– case series. Lupus. [Internet]. 2014 Aug [cited 23/08/2018]; 23(9):945-8. Disponible en: https://journals.sagepub.com/doi/abs/10.1177/0961203314530487?rfr_dat=cr_pub%3Dpubmed&url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&journalCode=lupa
12. Mattos P, Mittermayer BS. Disease activity in systemic lupus erythematosus patients with end-stage renal disease: systematic review of the literatura. Clin Rheumatol [Internet]. 2012 Jun [citado 23/08/2018]; 31(6):897-905. Disponible en: https://link.springer.com/article/10.1007%2Fs10067-012-1957-9
13. Contreras G, Lenz O, Pardo V, Borja E, Cely C. Outcomes in African Americans and Hispanics with lupus nephritis. Kidney Int [Internet]. 2006 [cited 23/08/2018]; 69(10):1846-51. Available from: https://www.kidney-international.org/article/S0085-2538(15)51340-9/fulltext
14. Pahl MV, Gollapudi S, Sepassi L Effect of end-stage renal disease on B-lymphocyte subpopulations, IL-7, BAFF and BAFF receptor expression. Nephrol Dial Transplant [Internet]. 2010 [cited 23/08/2018]; 25(1):205-12. Available from: https://academic.oup.com/ndt/article-lookup/doi/10.1093/ndt/gfp397
15. Lim WH, Kireta S, Russ GR, Coates PT. Uremia impairs blood dendritic cell function in hemodialysis patients. Kidney Int [internet] 2007 [citado 23/08/2018]; 71(11):1122-31. Disponible en: https://www.kidney-international.org/article/S0085-2538(15)52275-8/fulltext
16. Cucchiari D, Graziani G1, Ponticelli C. The dialysis scenario in patients with systemic lupus erythematosus. Neph Dial Transp. [Internet]. 2014 Aug [cited 23/08/2018];29(8):1507-1513. Available from: https://academic.oup.com/ndt/article/29/8/1507/1938224
17. Ribeiro FM, Leite MA, Velarde GC, Fabris CL, Santos RC. Activity of systemic lupus erythematosus in end-stage renal disease patients: study in a Brazilian cohort. Am J Nephrol. [Internet]. 2005 [cited 23/08/2018]; 25(6):596–603. Available from: https://www.karger.com/Article/Abstract/89708
18. Kang SH, Chung BH, Choi SR, Lee JY, Park HS, In-O S. Comparison of clinical outcomes by different renal replacement therapy in patients with end-stage renal disease secondary to lupus nephritis. Korean J Intern Med [Internet]. 2011 [cited 23/08/2018]; 26(1):60-67. Available from: http://kjim.org/journal/view.php?doi=10.3904/kjim.2011.26.1.60
19. Nossent HC, Swaak TJ, Berden JH: Systemic lupus erythematosus: analysis of disease activity in 55 patients with end-stage renal failure treated with hemodialysis or continuous ambulatory peritoneal dialysis. Dutch Working Party on LES. Am J Med [Internet].1990 [citado 23/08/2018]; 89(2): 169–74. Available from: https://www.ncbi.nlm.nih.gov/pubmed/2382665
20. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. Arthritis Rheum [internet] 1992 [cited 23/08/2018]; 35(6):630–640. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1002/art.1780350606?sid=nlm%3Apubmed
21. Conti G, Amore A, Chiesa M, Mancuso D, Cirina P, Mengozzi G, et al. Procalcitonin as a marker of micro-inflammation in hemodialysis. J Nephrol [Internet]. 2005 [cited 23/08/2018]; 18(3): 282–288. Disponible en: https://www.researchgate.net/publication/7731673_Procalcitonin_as_a_marker_of_micro-inflammation_in_hemodialysis
22. Sciascia S, Ceberio L, Garcia-Fernandez C, Roccatello D, Karim Y, Cuadrado MJ, et al. Systemic lupus erythematosus and infections: clinical importance of conventional and upcoming biomarkers. Autoimmun Rev [Internet]. 2012 [citado 23/08/2018]; 12(2): 157–163. Available from: https://www.sciencedirect.com/science/article/abs/pii/S1568997212000791?via%3Dihub
23. Broder A, Khattri S, Patel R, Putterman C. Undertreatment of disease activity in systemic lupus erythematosus patients with endstage renal failure is associated with increased all-cause mortality. J Rheumatol [Internet]. 2011 [cited 23/08/2018]; 38(11): 2382–2389. Available from: http://www.jrheum.org/content/38/11/2382.long
24. Lewis MJ, Jawad A. The effect of ethnicity and genetic ancestry on the epidemiology, clinical features and outcome of systemic lupus erythematosus. Rheumatology (Oxford). [Internet]. 2017 Apr [internet]; 56(suppl_1):i67-i77. Disponible en: https://academic.oup.com/rheumatology/article/56/suppl_1/i67/2629213
25. Ocampo-Piraquive V, Nieto-Aristizábal I, Cañas CA, Tobón GJ. Mortality in systemic lupus erythematosus: causes, predictors and interventions. Expert Rev Clin Immunol. [Internet]. 2018 [citado 23/08/2018]; 14(18):1043-1053. Disponible en: https://www.tandfonline.com/doi/abs/10.1080/1744666X.2018.1538789?journalCode=ierm20
26. Pons-Estel B, Catoggio L, Cardiel M, Soriano E, Gentiletti S, Villa A, et al. The GLADEL multinational Latin American prospective inception cohort of 1,214 patients with systemic lupus erythematosus: ethnic and disease heterogeneity among "Hispanics". Medicine (Baltimore). [Internet]. 2004 Jan [citado 23/08/2018]; 83(1):1-17. Disponible en: https://insights.ovid.com/pubmed?pmid=14747764
Descargar PDF
